HomeCompareCBIXF vs BTI

CBIXF vs BTI: Dividend Comparison 2026

CBIXF yields 18.60% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CBIXF wins by $29.3K in total portfolio value
10 years
CBIXF
CBIXF
● Live price
18.60%
Share price
$10.75
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$67.0K
Annual income
$5,789.69
Full CBIXF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — CBIXF vs BTI

📍 CBIXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBIXFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBIXF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBIXF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBIXF
Annual income on $10K today (after 15% tax)
$1,581.40/yr
After 10yr DRIP, annual income (after tax)
$4,921.24/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, CBIXF beats the other by $2,552.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBIXF + BTI for your $10,000?

CBIXF: 50%BTI: 50%
100% BTI50/50100% CBIXF
Portfolio after 10yr
$52.4K
Annual income
$4,288.17/yr
Blended yield
8.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

CBIXF
No analyst data
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBIXF buys
0
BTI buys
0
No recent congressional trades found for CBIXF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBIXFBTI
Forward yield18.60%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$67.0K$37.7K
Annual income after 10y$5,789.69$2,786.64
Total dividends collected$36.7K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CBIXF vs BTI ($10,000, DRIP)

YearCBIXF PortfolioCBIXF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$12,560$1,860.47$11,299$598.92+$1.3KCBIXF
2$15,624$2,183.95$12,794$703.91+$2.8KCBIXF
3$19,256$2,538.85$14,518$829.07+$4.7KCBIXF
4$23,529$2,924.42$16,513$978.64+$7.0KCBIXF
5$28,515$3,339.49$18,827$1,157.84+$9.7KCBIXF
6$34,294$3,782.47$21,518$1,373.12+$12.8KCBIXF
7$40,945$4,251.39$24,657$1,632.46+$16.3KCBIXF
8$48,556$4,743.96$28,329$1,945.74+$20.2KCBIXF
9$57,212$5,257.64$32,637$2,325.33+$24.6KCBIXF
10$67,007$5,789.69$37,708$2,786.64+$29.3KCBIXF

CBIXF vs BTI: Complete Analysis 2026

CBIXFStock

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases to use in the study of kinase-molecule interactions. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, ClariCELL kinase cell-based assay, crystallization, weak affinity chromatography, and tyrosine kinase cell-based assay services, as well as custom production of ultra-pure proteins for crystallography. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was founded in 2003 and is based in Kobe, Japan.

Full CBIXF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this CBIXF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBIXF vs SCHDCBIXF vs JEPICBIXF vs OCBIXF vs KOCBIXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.